• Explore /
  • Poster
  • / An open label phase I study to evaluate the safety and efficacy of OBP-301 with pembrolizumab in patients with advanced solid tumors.

An open label phase I study to evaluate the safety and efficacy of OBP-301 with pembrolizumab in patients with advanced solid tumors.

Abstract Poster

Authors

null

Takashi Kojima

Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan

Takashi Kojima , Toshiyoshi Fujiwara , Yasuhiro Shirakawa , Hiromi Ono , Masako Nakamoto , Hiromi Hasegawa , Nami Hirano , Masashi Wakabayashi , Shogo Nomura , Yosuke Togashi , Hiroyoshi Nishikawa , Akihiro Sato , Atsushi Ohtsu , Toshihiko Doi

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2018 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics—Immunotherapy

Track

Developmental Therapeutics and Translational Research

Sub Track

Immune Checkpoint Inhibitors

Clinical Trial Registration Number

NCT03172819

Citation

J Clin Oncol 36, 2018 (suppl; abstr TPS3117)

DOI

10.1200/JCO.2018.36.15_suppl.TPS3117

Abstract #

TPS3117

Poster Bd #

323a

Abstract Disclosures

Similar Posters

First Author: Judy S. Wang

First Author: Jacob Stephen Thomas

First Author: Mohamed Shanshal

First Author: Jie Wang